|
2-(3,6-DIHYDROXYPHENYL)ACETIC ACID
|
DB08327 |
|
|
Cauliflower
|
DB10643 |
[Cauliflower allergenic extract is used in allergenic testing.] |
|
PF-04691502
|
DB11974 |
[PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).] |
|
PANTOTHENYL-AMINOETHANOL-11-PIVALIC ACID
|
DB08328 |
|
|
Sulthiame
|
DB08329 |
|
|
Sweet potato
|
DB10648 |
[Sweet potato allergenic extract is used in allergenic testing.] |
|
Elagolix
|
DB11979 |
[Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain [F815].
It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review [F815], this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain.] |
|
Parsley
|
DB10647 |
[Parsley allergenic extract is used in allergenic testing.] |
|
Glasdegib
|
DB11978 |
[Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of the benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with a low molecular weight, potent inhibitory activity and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed.[A40310]
Glasdegib was developed by Pfizer Inc and approved on November 21, 2018, by the FDA for the treatment of Acute Myeloid Leukemia.[L4894]] |
|
Brussels sprout
|
DB10642 |
[Brussels sprout allergenic extract is used in allergenic testing.] |
|
Tesevatinib
|
DB11973 |
[Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.
Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression. In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.] |
|
Kiwi fruit
|
DB10641 |
[Kiwi fruit allergenic extract is used in allergenic testing.] |
|
Rilotumumab
|
DB11972 |
[Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.] |
|
Vilaprisan
|
DB11971 |
[Vilaprisan has been used in trials studying the treatment of Leiomyoma and Clinical Trial, Phase I.] |
|
Beet
|
DB10640 |
[Beet allergenic extract is used in allergenic testing.] |
|
Burixafor
|
DB11970 |
[Burixafor has been used in trials studying the treatment of Multiple Myeloma, Hodgkin's Disease, and Non-hodgkin's Lymphoma.] |
|
DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
|
DB08320 |
|
|
(1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol
|
DB08321 |
|
|
2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID
|
DB08322 |
|
|
3-OXO-N-[(3S)-2-OXOPYRROLIDIN-3-YL]DODECANAMIDE
|
DB08323 |
|
